Alnylam Pharmaceuticals Inc (ALNY)
NASDAQ · Healthcare
Alnylam Pharmaceuticals Inc Shareholder Equity 2008–2025
Alnylam Pharmaceuticals Inc annual shareholder equity history from 2009 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Alnylam Pharmaceuticals Inc shareholder equity as of December 31, 2025: 789.2M, a 1076.33% increase year-over-year.
- Alnylam Pharmaceuticals Inc shareholder equity for 2025 were 789.2M, a 1076.33% increase from 2024.
- Alnylam Pharmaceuticals Inc shareholder equity for 2024 were 67.1M, a 130.41% decrease from 2023.
- Alnylam Pharmaceuticals Inc shareholder equity for 2023 were -220.6M, a 39.45% increase from 2022.
- Alnylam Pharmaceuticals Inc shareholder equity for 2022 were -158.2M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Alnylam Pharmaceuticals Inc Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $789 |
| 2024 | $67 |
| 2023 | $-221 |
| 2022 | $-158 |
| 2021 | $588 |
| 2020 | $1,016 |
| 2019 | $1,439 |
| 2018 | $1,302 |
| 2017 | $1,766 |
| 2016 | $920 |
| 2010 | $158 |
| 2009 | $178 |
Alnylam Pharmaceuticals Inc Shareholder Equity — FAQ
Alnylam Pharmaceuticals Inc (ALNY) shareholder equity over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ALNY's shareholder equity history?
The chart and table above show Alnylam Pharmaceuticals Inc's shareholder equity by year and by quarter, including the growth rate.